Traditional drug development in Alzheimer's disease is taking too narrow an approach by focusing intensively on the buildup of amyloid beta-protein in the brain, Dr. Nixon says.

传统的治疗老年痴呆症的药物研发思路仅仅集中在淀粉样β蛋白的累积上，Nixon博士说。

youdao

People with the disease get plaques in their brains made up of a small protein called amyloid-beta, which clumps together and disrupts brain signals.

得了这种病的人大脑里面的血小板形成一种叫做淀粉样蛋白的蛋白质，这种蛋白质聚集在一起打乱了大脑发出的信号。

youdao

He has tested it so far in mice, and found the animals have better memory and other cognitive skills and fewer clumps of beta-amyloid and tau protein.

目前的实验对象为老鼠。他还发现动物具有更强的记忆力和其他认知能力，更少的贝塔淀粉样和tau蛋白质凝结。

youdao

Most researchers are focusing on blocking the formation of amyloid-beta protein or removing it from the brain, either before or after deposits are formed.

FORBES: Solving The Fatal Puzzle Of Alzheimer's Disease

Harvard University researchers conducted experiments on mice using oligomers, a soluble form of amyloid-beta protein, which is the key compound in brain plaque and a hallmark of Alzheimer's.

WSJ: Why Young Children Don't Notice Coming Cars

To be specific, Merck (MRK) will test a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, which the drugmaker notes is the first drug with this type of mechanism to advance to this stage of clinical research.

FORBES: Merck Makes A 'Speculative' Step Into Alzheimer's